[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2007/30361,2007,A2Locationinpatent:Page/Pagecolumn59
[2]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2007/30366,2007,A1Locationinpatent:Page/Pagecolumn152;156
[3]Locationinpatent:schemeortableHornberger,KeithR.;Badiang,JenniferG.;Salovich,JamesM.;Kuntz,KevinW.;Emmitte,KyleA.;Cheung,Mui[TetrahedronLetters,2008,vol.49,#44,p.6348-6351]
[4]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2009/2916,2008,A2Locationinpatent:Page/Pagecolumn34-35
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
Journal: Oncotarget 20111201
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Journal: Cancer research 20090901
Title: Olmos D, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 15;17(10):3420-30.
Title: Degenhardt Y, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010 Jul;9(7):2079-89
Title: Gilmartin AG, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009 Sep 1;69(17):6969-77.
Title: Chou YS, et al. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016 Mar;48(3):1187-94.
